Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment By Ogkologos - June 16, 2026 214 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR October is National Dental Hygiene Month October 1, 2020 FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications December 10, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab July 8, 2021 Professor Ian Tomlinson: “Philanthropy is priceless to science” June 3, 2021 Load more HOT NEWS ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March NCI-MATCH Update: More Labs, New Arms, and Initial Findings When Breast Cancer Patient Comes Into His Shop, Barber Shaves His... seven Interesting Facts about Malignant tumors Boy Between the sheets
